News Lilly nets Scorpion cancer drug in $2.5bn licensing deal Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.
News GSK confirms plan to buy cancer firm IDRx for $1bn GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.
News Galapagos unveils plan to split, hiving off its drugs unit Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.
News J&J says Rybrevant combo has survival edge over Tagrisso Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.
News GSK bags breakthrough status for bone cancer drug GSK has claimed its second breakthrough designation from the FDA for B7-H3-targeted ADC, this time in osteosarcoma.
R&D Sponsored 12 Questions with Peter Wickersham Peter Wickersham is the Vice President and General Manager of Gilead Sciences UK & Ireland, and a leader in HIV treatment, liver disease, and oncology.
News UK offers meningitis jab to young people after outbreak The UK government has responded to calls to broaden vaccinations for meningitis B, offering the jab to "thousands" of young people this summer.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
